Atea Pharmaceuticals, Inc. (AVIR) Stock Forecast
AVIR analyst forecast
as of October 18, 2026- Analyst consensus
- Buy 4.33 / 5 from 3 analysts
- Price target
- $9.42 average of analyst targets
- Upside to target
- +118.0% from the latest close
- Next earnings
- November 11, 2026 EPS estimate $-0.50
- 52-week range
- $2.96 – $6.15
AVIR analyst ratings
3 analystsNumber of analysts at each rating.
AVIR price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
AVIR earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.51 | −$0.59 | −$0.42 | −$0.53 | +4.7% | 2 |
| Current fiscal year (2026) | −$1.99 | −$2.21 | −$1.76 | −$1.94 | −2.3% | 2 |
| Next fiscal year (2027) | −$1.48 | −$1.76 | −$1.20 | −$1.99 | +25.4% | 2 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
AVIR revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0 | $0 | $0 | 0.0% | 1 |
| Current fiscal year (2026) | $0 | $0 | $0 | 0.0% | 1 |
| Next fiscal year (2027) | $30.0M | $0 | $60.0M | 0.0% | 2 |
AVIR EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
AVIR revenue: reported and forecast
AVIR EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.55 | −$0.55 | −$0.55 | −$0.55 | −$0.51 | −7.3% | 1 up · 1 down |
| Current fiscal year (2026) | −$1.65 | −$1.93 | −$1.93 | −$1.93 | −$1.99 | +20.3% | 0 up · 2 down |
| Next fiscal year (2027) | −$1.38 | −$1.39 | −$1.39 | −$1.39 | −$1.48 | +7.2% | 0 up · 2 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
AVIR earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; AVIR beat in 7 of 12.
What analysts expect from AVIR
3 analysts cover Atea Pharmaceuticals; their consensus rating is buy (4.33 on a 1–5 scale, where 5 is a strong buy). The average price target is $9.42, 118.0% above the latest close of $4.32. Analysts expect earnings of −$1.99 per share for 2026, −2.3% from a year earlier. For 2027 the average estimate is −$1.48 per share on revenue of $30.0 million. Atea Pharmaceuticals beat the EPS estimate in 7 of the last 12 quarters.
Related: AVIR income statement, AVIR key metrics, AVIR chart. See the AVIR stock overview for the latest quote and news.
AVIR forecast FAQ
What is Atea Pharmaceuticals's price target?
The average analyst price target for Atea Pharmaceuticals is $9.42, 118.0% above the latest close of $4.32.
Is Atea Pharmaceuticals a buy, hold or sell?
Of 3 analysts covering Atea Pharmaceuticals, 2 rate it a strong buy, 0 a buy, 1 a hold, 0 a sell and 0 a strong sell, a consensus of buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Atea Pharmaceuticals's EPS forecast?
Analysts forecast −$1.99 per share for 2026 (range −$2.21 to −$1.76); for 2027 the estimate is −$1.48.
When does Atea Pharmaceuticals report earnings?
Atea Pharmaceuticals is expected to report results for the quarter ending September 30, 2026 on November 11, 2026 after the market closes; the EPS estimate is $-0.50.
Does Atea Pharmaceuticals usually beat earnings estimates?
Atea Pharmaceuticals reported EPS at or above the analyst estimate in 7 of the last 12 quarters.